Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

This cross-sectional study included adults in remission after CAR T-cell therapy for multiple myeloma or B-cell lymphoma who were within 1-5 years post-treatment. We used bivariate analyses to measure ...

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

Short-term nutritional state can reshape T cell metabolism, with post-meal lipid metabolism enhancing T cell metabolic ...

Chimeric antigen receptor (CAR) T-cell therapy is one of oncology's most powerful ideas: Harvest a cancer patient's own ...

Chimeric antigen receptor-T (CAR-T) cell therapy represents a major breakthrough in cancer immunotherapy, providing remarkable clinical benefits for ...

This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic ...

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

CAR-T cell therapy works well in blood cancers, but many patients still become resistant. A key reason is the presence of CAR ...